Literature DB >> 25405901

B‑cell translocation gene 1 serves as a novel prognostic indicator of hepatocellular carcinoma.

Mitsuro Kanda1, Hiroyuki Sugimoto1, Shuji Nomoto1, Hisaharu Oya1, Soki Hibino1, Dai Shimizu1, Hideki Takami1, Ryoji Hashimoto1, Yukiyasu Okamura2, Suguru Yamada1, Tsutomu Fujii1, Goro Nakayama1, Masahiko Koike1, Michitaka Fujiwara1, Yasuhiro Kodera1.   

Abstract

Although the B‑cell translocation gene 1 (BTG1) plays an important role in apoptosis and negatively regulates cell proliferation, BTG1 expression in hepatocellular carcinoma (HCC) has not been evaluated. In this study expression analysis of BTG1 was conducted to clarify the role of BTG1 in the initiation of HCC carcinogenesis and progression. BTG1 mRNA expression levels were determined for HCC cell lines and 151 surgical specimen pairs using quantitative real‑time reverse transcription polymerase chain reaction (RT‑qPCR) assay. The mutational and methylation status of HCC cell lines were analyzed via high resolution melting (HRM) analysis and direct sequencing analysis to elucidate the regulatory mechanisms of BTG1 expression. The expression and distribution of the BTG1 protein in liver tissues were evaluated using immunohistochemistry (IHC). Decreased expression of BTG1 mRNA was confirmed in the majority of HCC cell lines (89%) and clinical HCC tissues (85%) compared with non‑cancerous liver tissues. Mutations or promoter hypermethylation were not identified in HCC cell lines. BTG1 mRNA expression levels were not influenced by background liver status. The pattern of BTG1 protein expression was consistent with that of BTG1 mRNA. Downregulation of BTG1 mRNA in HCC was significantly associated with shorter disease‑specific and recurrence‑free survival rates. Multivariate analysis of disease‑specific survival rates identified BTG1 mRNA downregulation as an independent prognostic factor for HCC (hazard ratio 2.12, 95% confidence interval 1.12‑4.04, P=0.022). Our results indicate that altered BTG1 expression might affect hepatocarcinogenesis and may represent a novel biomarker for HCC carcinogenesis and progression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25405901     DOI: 10.3892/ijo.2014.2762

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  21 in total

1.  Identification of BTG1 Status in Solid Cancer for Future Researches Using a System Review and Meta-analysis.

Authors:  Xiu-Qiong Chen; Fan-Qiao Meng; Hua Xiong; Ya-Li Wang; Wen-Hua Tang; Yan-Mei Zou
Journal:  Curr Med Sci       Date:  2020-03-13

2.  Prognostic relevance of SAMSN1 expression in gastric cancer.

Authors:  Mitsuro Kanda; Dai Shimizu; Satoshi Sueoka; Shuji Nomoto; Hisaharu Oya; Hideki Takami; Kazuhiro Ezaka; Ryoji Hashimoto; Yuri Tanaka; Daisuke Kobayashi; Chie Tanaka; Suguru Yamada; Tsutomu Fujii; Goro Nakayama; Hiroyuki Sugimoto; Masahiko Koike; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Oncol Lett       Date:  2016-10-06       Impact factor: 2.967

Review 3.  Recent advances in the molecular diagnostics of gastric cancer.

Authors:  Mitsuro Kanda; Yasuhiro Kodera
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

4.  miR-511 promotes the proliferation of human hepatoma cells by targeting the 3'UTR of B cell translocation gene 1 (BTG1) mRNA.

Authors:  Shu-Qin Zhang; Zhe Yang; Xiao-Li Cai; Man Zhao; Ming-Ming Sun; Jiong Li; Guo-Xing Feng; Jin-Yan Feng; Li-Hong Ye; Jun-Qi Niu; Xiao-Dong Zhang
Journal:  Acta Pharmacol Sin       Date:  2017-06-12       Impact factor: 6.150

Review 5.  Molecular mechanisms of peritoneal dissemination in gastric cancer.

Authors:  Mitsuro Kanda; Yasuhiro Kodera
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

6.  NRAGE promotes the malignant phenotype of hepatocellular carcinoma.

Authors:  Dai Shimizu; Mitsuro Kanda; Hiroyuki Sugimoto; Satoshi Sueoka; Hideki Takami; Kazuhiro Ezaka; Yuri Tanaka; Ryoji Hashimoto; Yukiyasu Okamura; Naoki Iwata; Chie Tanaka; Suguru Yamada; Tsutomu Fujii; Goro Nakayama; Masahiko Koike; Shuji Nomoto; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Oncol Lett       Date:  2016-01-15       Impact factor: 2.967

Review 7.  Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma.

Authors:  Mitsuro Kanda; Hiroyuki Sugimoto; Yasuhiro Kodera
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

8.  BTG1 expression correlates with pathogenesis, aggressive behaviors and prognosis of gastric cancer: a potential target for gene therapy.

Authors:  Hua-chuan Zheng; Jing Li; Dao-fu Shen; Xue-feng Yang; Shuang Zhao; Ya-zhou Wu; Yasuo Takano; Hong-zhi Sun; Rong-jian Su; Jun-sheng Luo; Wen-feng Gou
Journal:  Oncotarget       Date:  2015-08-14

9.  Metastatic pathway-specific transcriptome analysis identifies MFSD4 as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer.

Authors:  Mitsuro Kanda; Dai Shimizu; Haruyoshi Tanaka; Masahiro Shibata; Naoki Iwata; Masamichi Hayashi; Daisuke Kobayashi; Chie Tanaka; Suguru Yamada; Tsutomu Fujii; Goro Nakayama; Hiroyuki Sugimoto; Masahiko Koike; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Oncotarget       Date:  2016-03-22

10.  An integrated multigene expression panel to predict long-term survival after curative hepatectomy in patients with hepatocellular carcinoma.

Authors:  Mitsuro Kanda; Kenta Murotani; Hiroyuki Sugimoto; Takashi Miwa; Shinichi Umeda; Masaya Suenaga; Masamichi Hayashi; Norifumi Hattori; Chie Tanaka; Daisuke Kobayashi; Suguru Yamada; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Oncotarget       Date:  2017-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.